Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on Wednesday, with a session volume of 89.21 million versus the average volume of 1.11 million, as per data from Benzinga Pro.Novo Nordisk A/S (NYSE:NVO) and Omeros on Wednesday announced an asset purchase and license agreement for the candidate drug zaltenibart (formerly OMS906) for rare blood and kidney disorders. ...